Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Tacrolimus is More Effective than Pimecrolimus For Atopic Dermatitis

02.08.2004


Data presented here today at the Academy 2004 meeting of the American Academy of Dermatology demonstrate that tacrolimus ointment is more effective than pimecrolimus cream in the treatment of adult and pediatric patients with atopic dermatitis (AD).



Overall results also revealed that in the same patient populations, both treatments have similar safety profiles including no statistical difference with regard to burning and stinging. These findings were presented by Alan Fleischer, M.D., study investigator, professor, chair and director of the General Dermatology Clinic, Wake Forest University Baptist Medical Center. They support preliminary data presented by Fleischer in February at the academy’s annual meeting.

“This study is the first, large, well-designed comparative trial to examine tacrolimus ointment and pimecrolimus cream in the same patient populations, including age, disease severity, length of treatment, efficacy endpoints and adverse events,” said Fleischer. “In this study, tacrolimus ointment seemed to work better for all severities of atopic dermatitis than pimecrolimus, including mild sufferers and particularly in severe patients.”


The six-week, randomized, investigator-blinded study evaluated 1,056 patients, including children as young as 2, with mild to severe AD. Treatment success was defined by the Investigator’s Global Atopic Dermatitis Assessment (IGADA) as “clear” or “almost clear.”

The first arm evaluated adult patients with mild to very severe AD. At six weeks, 46 percent of 210 patients treated with tacrolimus ointment 0.1 percent were rated as “clear” or “almost clear” compared with 27 percent of 203 patients receiving pimecrolimus cream 1 percent. The second arm evaluated tacrolimus ointment 0.1 percent or pimecrolimus cream 1 percent in pediatric patients ages 2 to 15 with moderate to very severe AD. Of 112 children treated with tacrolimus ointment, 32 percent achieved treatment success compared with 18 percent of children treated with pimecrolimus cream. The third arm evaluated tacrolimus ointment 0.03 percent or pimecrolimus cream 1 percent in pediatric patients with mild AD. Forty-seven percent of 208 children treated with tacrolimus ointment achieved treatment success compared with 41 percent of 217 patients using pimecrolimus cream.

“This study revealed that tacrolimus and pimecrolimus patients had a comparable tolerability including burning and stinging,” said Fleischer. “Patients treated with tacrolimus ointment for all severities of atopic dermatitis experienced a greater and more rapid reduction in itching symptoms, which is key to improving the quality of life for these patients.”

Efficacy of the two treatments was comprehensively measured at day 1 and weeks 1, 3 and 6, using the physician-rated Body Surface Area (BSA) assessment, and the six-point IGADA, which evaluated the major symptoms of AD. An Eczema Area and Severity Index score also was calculated and a patient’s evaluation of itch was recorded at each visit.

“This study supports existing data that show that tacrolimus and pimecrolimus have the same safety profile and comparable tolerability,” said Fleischer. “Tacrolimus works more rapidly at the skin’s surface than pimecrolimus, yet existing data indicate that neither medication showed a trend toward higher blood accumulation over time deeming them equally safe.”

The study was funded by Fujisawa Healthcare Inc., which makes tacrolimus ointment. It is available by prescription in two concentrations for adults, 0.03 percent and 0.1 percent. For children ages 2 to 15, the 0.03 percent concentration is indicated.

Topical immunomodulators, a nonsteroidal class of topical agents that are safer than corticosteroids, are the first new class of prescription drugs to be developed in more than 40 years for the treatment of AD. The FDA approved tacrolimus ointment, the steroid-free alternative, in December 2000 for short-term and intermittent long-term therapy to treat the signs and symptoms of moderate to severe AD in children and adults. Pimecrolimus cream 1 percent was approved in December 2001 for short-term and intermittent long-term treatment of mild to moderate AD in patients ages 2 and older.

| newswise
Further information:
http://www.wfubmc.edu

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>